UNSPSC 51291709: Bipenamol

This classification denotes a serotonin agonist with the molecular formula C14H15NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49DCB7156W, chemically known as [2-[2-(aminomethyl)phenyl]sulfanylphenyl]methanol but generally known as cericlamine, which bears US NIH Compound Identifier 43961. European Medicines Agency schedules Bipenamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05842MIG.

The term BIPENAMOL is an International Non-Proprietary Name (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25.) Most nations schedule bipenamol under HS 29309085 and SITC 51549. As of Q4 2014, BIPENAMOL remains the US FDA Preferred Term for this commodity. Bipenamol bears US NLM identifiers UMLS ID C2698511 and NCI Concept Code C79854. SMILES: C1=CC=C(C(=C1)CN)SC2=CC=CC=C2CO.

UNSPSC 51291709 Bipenamol is a Commodity code that covers pharmaceutical products, though recent state and local solicitations show minimal activity directly aligned with bipenamol procurement. The code's nominal scope encompasses individual pharmaceutical compounds, but state and local bodies are instead soliciting broader pharmacy benefit programs, pharmaceutical distribution networks, and emergency medical supplies. Issuing bodies across the recent opportunities include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The activity reflects procurement of naloxone systems, generic multi-source pharmaceuticals with OTC products, and direct-to-manufacturer prescription programs rather than single-compound pharmaceutical purchases.

Geographic activity appears concentrated in Florida, Texas, and Minnesota, with multistate coordination through purchasing cooperatives. Representative recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with one-year renewal option and quarterly deliveries to the Seminole County Community Health Building in Sanford, with response deadline of July 26, 2023; Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor information on direct-to-manufacturer prescription capabilities for a future pharmacy benefit initiative; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent procurement activity specifically for bipenamol and appears misaligned with actual state and local pharmaceutical buying patterns, which favor broad-based distribution agreements and emergency response supplies over single-compound acquisitions.